JP2019501671A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501671A5 JP2019501671A5 JP2018555311A JP2018555311A JP2019501671A5 JP 2019501671 A5 JP2019501671 A5 JP 2019501671A5 JP 2018555311 A JP2018555311 A JP 2018555311A JP 2018555311 A JP2018555311 A JP 2018555311A JP 2019501671 A5 JP2019501671 A5 JP 2019501671A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- inhibitor
- immune
- ligand
- promoter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700605 Viruses Species 0.000 claims description 82
- 108090000623 proteins and genes Proteins 0.000 claims description 43
- 230000037361 pathway Effects 0.000 claims description 32
- 239000003112 inhibitor Substances 0.000 claims description 26
- 206010028980 Neoplasm Diseases 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 18
- 239000000556 agonist Substances 0.000 claims description 17
- 239000002246 antineoplastic agent Substances 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 16
- 230000003213 activating effect Effects 0.000 claims description 15
- 241000700584 Simplexvirus Species 0.000 claims description 10
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 230000008488 polyadenylation Effects 0.000 claims description 8
- 241000713813 Gibbon ape leukemia virus Species 0.000 claims description 7
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 7
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 7
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims description 7
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims description 7
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims description 6
- 108010029697 CD40 Ligand Proteins 0.000 claims description 6
- 102100032937 CD40 ligand Human genes 0.000 claims description 6
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims description 6
- 241000712079 Measles morbillivirus Species 0.000 claims description 6
- 230000000139 costimulatory effect Effects 0.000 claims description 6
- 230000001177 retroviral effect Effects 0.000 claims description 6
- 230000008685 targeting Effects 0.000 claims description 6
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 claims description 5
- 244000309459 oncolytic virus Species 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 241000713730 Equine infectious anemia virus Species 0.000 claims description 4
- 108090000288 Glycoproteins Proteins 0.000 claims description 4
- 102000003886 Glycoproteins Human genes 0.000 claims description 4
- 101100508081 Human herpesvirus 1 (strain 17) ICP34.5 gene Proteins 0.000 claims description 4
- 102100034980 ICOS ligand Human genes 0.000 claims description 4
- 101710093458 ICOS ligand Proteins 0.000 claims description 4
- 241001559185 Mammalian rubulavirus 5 Species 0.000 claims description 4
- 241000713821 Mason-Pfizer monkey virus Species 0.000 claims description 4
- 241000713869 Moloney murine leukemia virus Species 0.000 claims description 4
- 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 claims description 4
- 102000004473 OX40 Ligand Human genes 0.000 claims description 4
- 108010042215 OX40 Ligand Proteins 0.000 claims description 4
- 101150027249 RL1 gene Proteins 0.000 claims description 4
- 241000711975 Vesicular stomatitis virus Species 0.000 claims description 4
- 230000004940 costimulation Effects 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 101150013553 CD40 gene Proteins 0.000 claims description 3
- 108010062802 CD66 antigens Proteins 0.000 claims description 3
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims description 3
- 102100031256 Cyclic GMP-AMP synthase Human genes 0.000 claims description 3
- 101710118064 Cyclic GMP-AMP synthase Proteins 0.000 claims description 3
- 102100025626 GTP-binding protein GEM Human genes 0.000 claims description 3
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 3
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 3
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 3
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims description 3
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 3
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 3
- 229940125563 LAG3 inhibitor Drugs 0.000 claims description 3
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 3
- 239000012270 PD-1 inhibitor Substances 0.000 claims description 3
- 239000012668 PD-1-inhibitor Substances 0.000 claims description 3
- 239000012271 PD-L1 inhibitor Substances 0.000 claims description 3
- 102100029198 SLAM family member 7 Human genes 0.000 claims description 3
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 3
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 3
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 3
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 3
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 3
- 230000000799 fusogenic effect Effects 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 230000015788 innate immune response Effects 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 230000035772 mutation Effects 0.000 claims description 3
- 210000000822 natural killer cell Anatomy 0.000 claims description 3
- 229940121655 pd-1 inhibitor Drugs 0.000 claims description 3
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 241001430294 unidentified retrovirus Species 0.000 claims description 3
- 108010046080 CD27 Ligand Proteins 0.000 claims description 2
- 102100027207 CD27 antigen Human genes 0.000 claims description 2
- 108010017987 CD30 Ligand Proteins 0.000 claims description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 2
- 108091006027 G proteins Proteins 0.000 claims description 2
- 102000030782 GTP binding Human genes 0.000 claims description 2
- 108091000058 GTP-Binding Proteins 0.000 claims description 2
- 108700002232 Immediate-Early Genes Proteins 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 101710169105 Minor spike protein Proteins 0.000 claims description 2
- 101710081079 Minor spike protein H Proteins 0.000 claims description 2
- 101800001693 R-peptide Proteins 0.000 claims description 2
- 241000702263 Reovirus sp. Species 0.000 claims description 2
- 102100021696 Syncytin-1 Human genes 0.000 claims description 2
- 102100021742 Syncytin-2 Human genes 0.000 claims description 2
- 101710091284 Syncytin-2 Proteins 0.000 claims description 2
- 108090000138 Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 claims description 2
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 claims description 2
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 claims description 2
- 101150085955 US11 gene Proteins 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 108700014844 flt3 ligand Proteins 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 230000004927 fusion Effects 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 108010037253 syncytin Proteins 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 8
- 241001068263 Replication competent viruses Species 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 230000033228 biological regulation Effects 0.000 claims 1
- 230000007699 co-inhibitory pathway Effects 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 5
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 241000282620 Hylobates sp. Species 0.000 description 1
- 241000282596 Hylobatidae Species 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022034569A JP2022078225A (ja) | 2016-01-08 | 2022-03-07 | 操作された腫瘍溶解性ウイルス |
| JP2024119344A JP2024153748A (ja) | 2016-01-08 | 2024-07-25 | 操作された腫瘍溶解性ウイルス |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1600381.6A GB201600381D0 (en) | 2016-01-08 | 2016-01-08 | Virus strain |
| GB1600381.6 | 2016-01-08 | ||
| GBGB1600380.8A GB201600380D0 (en) | 2016-01-08 | 2016-01-08 | Modified virus |
| GB1600382.4 | 2016-01-08 | ||
| GB1600380.8 | 2016-01-08 | ||
| GBGB1600382.4A GB201600382D0 (en) | 2016-01-08 | 2016-01-08 | Engineered virus |
| PCT/GB2017/050038 WO2017118866A1 (en) | 2016-01-08 | 2017-01-09 | Engineered virus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022034569A Division JP2022078225A (ja) | 2016-01-08 | 2022-03-07 | 操作された腫瘍溶解性ウイルス |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019501671A JP2019501671A (ja) | 2019-01-24 |
| JP2019501671A5 true JP2019501671A5 (enExample) | 2020-01-30 |
| JP7038664B2 JP7038664B2 (ja) | 2022-03-18 |
Family
ID=57796748
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555309A Active JP6959258B2 (ja) | 2016-01-08 | 2017-01-09 | 改変された腫瘍溶解性ウイルス |
| JP2018555310A Active JP7038065B2 (ja) | 2016-01-08 | 2017-01-09 | 腫瘍溶解性ウイルス株 |
| JP2018555311A Active JP7038664B2 (ja) | 2016-01-08 | 2017-01-09 | 操作された腫瘍溶解性ウイルス |
| JP2021163811A Active JP7295192B2 (ja) | 2016-01-08 | 2021-10-05 | 改変された腫瘍溶解性ウイルス |
| JP2022034569A Pending JP2022078225A (ja) | 2016-01-08 | 2022-03-07 | 操作された腫瘍溶解性ウイルス |
| JP2023094818A Pending JP2023113885A (ja) | 2016-01-08 | 2023-06-08 | 改変された腫瘍溶解性ウイルス |
| JP2024119344A Pending JP2024153748A (ja) | 2016-01-08 | 2024-07-25 | 操作された腫瘍溶解性ウイルス |
| JP2025128636A Pending JP2025163138A (ja) | 2016-01-08 | 2025-07-31 | 改変された腫瘍溶解性ウイルス |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555309A Active JP6959258B2 (ja) | 2016-01-08 | 2017-01-09 | 改変された腫瘍溶解性ウイルス |
| JP2018555310A Active JP7038065B2 (ja) | 2016-01-08 | 2017-01-09 | 腫瘍溶解性ウイルス株 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021163811A Active JP7295192B2 (ja) | 2016-01-08 | 2021-10-05 | 改変された腫瘍溶解性ウイルス |
| JP2022034569A Pending JP2022078225A (ja) | 2016-01-08 | 2022-03-07 | 操作された腫瘍溶解性ウイルス |
| JP2023094818A Pending JP2023113885A (ja) | 2016-01-08 | 2023-06-08 | 改変された腫瘍溶解性ウイルス |
| JP2024119344A Pending JP2024153748A (ja) | 2016-01-08 | 2024-07-25 | 操作された腫瘍溶解性ウイルス |
| JP2025128636A Pending JP2025163138A (ja) | 2016-01-08 | 2025-07-31 | 改変された腫瘍溶解性ウイルス |
Country Status (13)
| Country | Link |
|---|---|
| US (13) | US10626377B2 (enExample) |
| EP (8) | EP3400291B2 (enExample) |
| JP (8) | JP6959258B2 (enExample) |
| KR (2) | KR20250026348A (enExample) |
| CN (3) | CN109415703B (enExample) |
| AU (2) | AU2017205216B2 (enExample) |
| CA (3) | CA3011009A1 (enExample) |
| DK (4) | DK3805376T3 (enExample) |
| ES (4) | ES2841300T5 (enExample) |
| IL (2) | IL260480B (enExample) |
| MX (1) | MX2018008413A (enExample) |
| SG (2) | SG11201805835WA (enExample) |
| WO (4) | WO2017118867A1 (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0107736A (pt) * | 2000-01-21 | 2002-11-19 | Biovex Ltd | Uso de uma cepa de vìrus não laboratorial, métodos para determinar se um gene tem um efeito sobre um fenótipo associado com um distúrbio dos sistemas nervosos periférico e central ou sobre uma célula dos sistemas nervosos periférico e central, para determinar se um gene codifica um antìgeno associado com uma infecção patogênica ou câncer, para determinar a adequabilidade de uma cepa de vìrus não laboratorial para modificação em uma cepa modificada, para determinar se um gene aumenta os efeitos anti-tumorais de um vìrus e para produzir uma cepa de vìrus não laboratorial oncolìtica, modificada, cepa de vìrus não laboratorial, uso de um gene, cepa hsv1 js1, composição farmacêutica, e, métodos para tratar um tumor em um indivìduo, para suprir um gene a um indivìduo e para tratar ou impedir um distúrbio do sistemas nervosos periférico e central |
| HUE037460T2 (hu) | 2005-12-02 | 2018-08-28 | Icahn School Med Mount Sinai | Nem-natív felületi fehérjéket prezentáló kiméra Newcastle disease vírusok és alkalmazásuk |
| US8901798B2 (en) | 2007-05-31 | 2014-12-02 | Regal Beloit America, Inc. | Switched reluctance machines with minimum stator core |
| US20160015760A1 (en) | 2013-03-14 | 2016-01-21 | Icahn School Of Medicine At Mount Sinai | Newcastle disease viruses and uses thereof |
| US20180133327A1 (en) | 2015-03-16 | 2018-05-17 | Amal Therapeutics Sa | Cell Penetrating Peptides and Complexes Comprising the Same |
| JP7032311B2 (ja) | 2015-07-16 | 2022-03-08 | バイオエクセル セラピューティクス，インコーポレイテッド | 免疫調節を使用してがんを処置するための新規手法 |
| MX2018008413A (es) | 2016-01-08 | 2019-02-20 | Replimune Ltd | Virus oncolitico modificado. |
| JP2019508063A (ja) | 2016-01-27 | 2019-03-28 | オンコラス， インコーポレイテッド | 腫瘍溶解性ウイルスベクター及びその使用 |
| CA3010779A1 (en) | 2016-03-16 | 2017-09-21 | Amal Therapeutics Sa | Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine |
| KR102323872B1 (ko) * | 2016-04-22 | 2021-11-08 | 임비라 컴퍼니 리미티드 | 암치료용 종양 용해성 단순 헤르페스 바이러스(oHSV) 절대 벡터 및 그 구조체의 구조 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| US20190336552A1 (en) | 2016-05-30 | 2019-11-07 | Astellas Pharma Inc. | Genetically engineered vaccinia viruses |
| US10888594B2 (en) | 2016-05-30 | 2021-01-12 | National University Corporation Tottori University | Genetically engineered vaccinia viruses |
| RU2021127872A (ru) | 2016-06-30 | 2021-11-09 | Онкорус, Инк. | Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов |
| KR102879364B1 (ko) | 2016-09-21 | 2025-11-04 | 아말 테라퓨틱스 에스에이 | 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체 |
| CN108261426B (zh) * | 2017-01-04 | 2019-04-05 | 杭州康万达医药科技有限公司 | 药物组合物及其在治疗肿瘤和/或癌症的药物中的应用 |
| GB201700350D0 (en) * | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
| EP3615934A1 (en) | 2017-04-28 | 2020-03-04 | Merck Sharp & Dohme Corp. | Biomarkers for cancer therapeutics |
| JOP20190256A1 (ar) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | فيروسات داء نيوكاسل واستخداماتها |
| SG11202000691XA (en) | 2017-07-26 | 2020-02-27 | Oncorus Inc | Oncolytic viral vectors and uses thereof |
| ES2975221T3 (es) | 2017-08-03 | 2024-07-04 | Amgen Inc | Muteínas de interleucina-21 y métodos de tratamiento |
| CN116003405A (zh) | 2017-09-08 | 2023-04-25 | 美国安进公司 | Kras g12c的抑制剂及其使用方法 |
| CN109554353B (zh) * | 2017-09-26 | 2021-08-06 | 杭州康万达医药科技有限公司 | 分离的重组溶瘤痘病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途 |
| WO2019093435A1 (ja) * | 2017-11-08 | 2019-05-16 | 国立大学法人 鹿児島大学 | 安全を確保しながら転移性がんまで効果的に治療可能な、搭載する免疫誘導遺伝子の最適発現レベルを与える発現制御システムを有する腫瘍溶解性ウイルス（腫瘍溶解性免疫治療） |
| CA3082117A1 (en) * | 2017-11-13 | 2019-05-16 | Bioxcel Therapeutics, Inc. | Methods and compositions for treating cancer by modifying multiple arms of the immune system |
| EP3731850A4 (en) | 2017-12-29 | 2021-12-01 | Oncorus, Inc. | ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES |
| JOP20200172A1 (ar) | 2018-01-12 | 2020-07-12 | Amgen Inc | الأجسام المضادة لـ pd-1 وطرق العلاج |
| WO2019147982A1 (en) * | 2018-01-26 | 2019-08-01 | Celldex Therapeutics, Inc. | Methods of treating cancer with dendritic cell mobilizing agents |
| GB201804473D0 (en) * | 2018-03-21 | 2018-05-02 | Valo Therapeutics Oy | Modified oncolytic adenoviruses |
| CN108635380A (zh) * | 2018-04-13 | 2018-10-12 | 北京唯源立康生物科技有限公司 | 重组溶瘤病毒组合物及其在制备用于治疗肿瘤的药物中的应用 |
| JP2021527694A (ja) * | 2018-06-21 | 2021-10-14 | レプリミュン リミテッド | 腫瘍溶解性ウイルスを用いた処置 |
| AU2019292580A1 (en) * | 2018-06-29 | 2021-02-04 | Krystal Biotech, Inc. | Compositions and methods for antibody delivery |
| CN109161561A (zh) * | 2018-08-09 | 2019-01-08 | 湖北科技学院 | 一种选择性杀灭前列腺癌细胞的新型溶瘤病毒及其构建方法 |
| EP3837277A4 (en) | 2018-08-17 | 2022-05-11 | Icahn School of Medicine at Mount Sinai | RECOMBINANT NEWCASTLE DISEASE VIRUSES AND THEIR USES IN THE PREVENTION OF RSV DISEASE OR HUMAN METAPNEUMOVIRUS INFECTION |
| CN119955743A (zh) * | 2018-09-10 | 2025-05-09 | 上海锦斯生物技术有限公司 | 修饰的溶瘤病毒、其组合物和用途 |
| TWI824020B (zh) | 2018-09-26 | 2023-12-01 | 日商安斯泰來製藥股份有限公司 | 藉由腫瘤溶解性牛痘病毒與免疫檢查點抑制劑併用之癌症療法以及用於其之醫藥組合物及組合醫藥 |
| EP3902529A1 (en) | 2018-12-27 | 2021-11-03 | Amgen Inc. | Lyophilized virus formulations |
| CN111606999B (zh) * | 2019-02-26 | 2022-09-06 | 南京惟亚德生物医药有限公司 | 兼具激活免疫共刺激信号通路和阻断免疫检查点的复制型溶瘤腺病毒及其应用 |
| JP7679303B2 (ja) * | 2019-03-05 | 2025-05-19 | アムジエン・インコーポレーテツド | がんを治療するための腫瘍溶解性ウイルスの使用 |
| TW202102543A (zh) | 2019-03-29 | 2021-01-16 | 美商安進公司 | 溶瘤病毒在癌症新輔助療法中之用途 |
| CN110054678B (zh) * | 2019-05-16 | 2023-04-18 | 中国医学科学院血液病医院（血液学研究所） | 一种膜结合型mFLT3LG蛋白及其应用 |
| CN110218707B (zh) * | 2019-05-29 | 2021-10-22 | 上海市公共卫生临床中心 | 一种新型溶瘤病毒及其制备方法和应用 |
| US20220273739A1 (en) * | 2019-08-05 | 2022-09-01 | National University Corporation Tokai National Higher Education And Research System | Combination drug for treating malignant tumor, pharmaceutical composition for treating malignant tumor, and pharmaceutical composition for malignant tumor treatment |
| CA3156880A1 (en) * | 2019-11-06 | 2021-05-14 | Memgen, Inc. | Replication-enhanced oncolytic adenoviruses |
| CN110982794B (zh) * | 2020-03-05 | 2020-06-16 | 北京唯源立康生物科技有限公司 | 一种修饰的单纯疱疹病毒 |
| CN110982795B (zh) * | 2020-03-05 | 2020-06-16 | 北京唯源立康生物科技有限公司 | 一种单纯疱疹病毒及其用途 |
| US20240216533A1 (en) * | 2020-03-05 | 2024-07-04 | Beijing Wellgene Company Ltd. | Herpes simplex virus and use thereof |
| JPWO2021193081A1 (enExample) * | 2020-03-23 | 2021-09-30 | ||
| US20230355804A1 (en) | 2020-06-29 | 2023-11-09 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| US11839659B2 (en) | 2020-07-02 | 2023-12-12 | Northwestern University | Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein |
| CN112941039A (zh) * | 2021-02-01 | 2021-06-11 | 南京大学 | 一种新型类囊泡溶瘤病毒及其在制备抗肿瘤药物上的应用 |
| DE102022104146A1 (de) | 2021-03-19 | 2022-09-22 | Yamada Manufacturing Co., Ltd. | Lenkvorrichtung |
| IL307223A (en) * | 2021-04-08 | 2023-11-01 | Immvira Biopharmaceuticals Co Ltd | Genetically modified oncolytic herpes simplex virus delivering chemokine and tumor associated/specific antigen |
| WO2022245808A1 (en) * | 2021-05-18 | 2022-11-24 | The Penn State Research Foundation | Oncolytic virus based cancer therapy |
| CN113583979B (zh) * | 2021-08-03 | 2022-11-22 | 杭州荣谷生物科技有限公司 | 一种重组溶瘤痘苗病毒、制备方法及其用途 |
| US20250128337A1 (en) | 2022-01-11 | 2025-04-24 | Mitsubishi Materials Corporation | Surface-coated cutting tool |
| WO2024055022A2 (en) * | 2022-09-08 | 2024-03-14 | Virogin Biotech Canada Ltd | Oncolytic virus expressing an immune cell engager for tumor targeting |
| WO2025248110A1 (en) * | 2024-05-31 | 2025-12-04 | Replimune Limited | An oncolytic herpes simplex virus (hsv) and an anti-pd-1 antibody for use in treating braf mutant melanoma |
| WO2026010067A1 (ko) * | 2024-07-01 | 2026-01-08 | 주식회사 피비이뮨테라퓨틱스 | 길항성 항-cd40 인간화 항체 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU594014B2 (en) | 1984-03-21 | 1990-03-01 | Research Corporation Technologies, Inc. | Recombinant DNA molecules |
| CA1282721C (en) | 1984-06-04 | 1991-04-09 | Bernard Roizman | Herpes simplex virus as a vector |
| US5288641A (en) | 1984-06-04 | 1994-02-22 | Arch Development Corporation | Herpes Simplex virus as a vector |
| DE3584341D1 (de) | 1984-08-24 | 1991-11-14 | Upjohn Co | Rekombinante dna-verbindungen und expression von polypeptiden wie tpa. |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5698531A (en) | 1989-03-31 | 1997-12-16 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5328688A (en) | 1990-09-10 | 1994-07-12 | Arch Development Corporation | Recombinant herpes simplex viruses vaccines and methods |
| US6770274B1 (en) | 1990-09-14 | 2004-08-03 | The General Hospital Corporation | Viral mutant HSV mediated destruction of neoplastic cells |
| US6040169A (en) | 1991-01-31 | 2000-03-21 | Medical Research Council | Herpes simplex virus-1 deletion variants and vaccines thereof |
| ES2183811T3 (es) | 1992-03-31 | 2003-04-01 | Arch Dev Corp | Tratamiento de enfermedades tumorigenas con un hsv modificado. |
| US6699468B1 (en) | 1994-06-23 | 2004-03-02 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
| JPH11513390A (ja) | 1995-10-06 | 1999-11-16 | アーチ デベロップメント コーポレイション | 細胞殺傷のウイルス増強のための方法および組成物 |
| US5824318A (en) | 1996-07-24 | 1998-10-20 | American Cyanamid Company | Avirulent herpetic viruses useful as tumoricidal agents and vaccines |
| GB9700411D0 (en) | 1997-01-10 | 1997-02-26 | Univ London | Eukaryotic gene expression cassette and uses thereof |
| US6379674B1 (en) | 1997-08-12 | 2002-04-30 | Georgetown University | Use of herpes vectors for tumor therapy |
| US7300774B1 (en) | 1999-12-09 | 2007-11-27 | The Regents Of The University Of California | Multimeric fusion proteins of the TNF superfamily ligands |
| US6428968B1 (en) | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
| MXPA02004736A (es) | 1999-11-12 | 2003-01-28 | Oncolytics Biotech Inc | Virus para el tratamiento de trastornos proliferativos celulares. |
| BR0107736A (pt) | 2000-01-21 | 2002-11-19 | Biovex Ltd | Uso de uma cepa de vìrus não laboratorial, métodos para determinar se um gene tem um efeito sobre um fenótipo associado com um distúrbio dos sistemas nervosos periférico e central ou sobre uma célula dos sistemas nervosos periférico e central, para determinar se um gene codifica um antìgeno associado com uma infecção patogênica ou câncer, para determinar a adequabilidade de uma cepa de vìrus não laboratorial para modificação em uma cepa modificada, para determinar se um gene aumenta os efeitos anti-tumorais de um vìrus e para produzir uma cepa de vìrus não laboratorial oncolìtica, modificada, cepa de vìrus não laboratorial, uso de um gene, cepa hsv1 js1, composição farmacêutica, e, métodos para tratar um tumor em um indivìduo, para suprir um gene a um indivìduo e para tratar ou impedir um distúrbio do sistemas nervosos periférico e central |
| US7749745B2 (en) | 2001-03-27 | 2010-07-06 | Georgetown University | Viral vectors and their use in therapeutic methods |
| GB0317511D0 (en) * | 2003-07-25 | 2003-08-27 | Biovex Ltd | Viral vectors |
| WO2006002394A2 (en) | 2004-06-24 | 2006-01-05 | New York University | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
| CA2586844A1 (en) | 2004-11-04 | 2006-05-11 | Pfizer Products Inc. | Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer |
| US9866961B2 (en) | 2004-12-01 | 2018-01-09 | Todd Beauchamp | Multi-channel loudspeaker enclosure with laterally projecting wings and method for orienting and driving multiple loudspeakers |
| TW200719913A (en) | 2005-03-08 | 2007-06-01 | Pharmacia & Upjohn Co Llc | Anti-madcam antibody compositions |
| SI2650020T1 (sl) | 2005-05-06 | 2017-03-31 | Providence Health & Services - Oregon Technology Transfer | Trimerični OX40 imunoglobulinski fuzijski protein in postopek za njegovo uporabo |
| EP1909849B1 (en) | 2005-06-23 | 2013-08-07 | The University Of Houston | Use of mutant herpes simplex virus-2 for cancer therapy |
| GB0522476D0 (en) | 2005-11-03 | 2005-12-14 | Biovex Ltd | Oncolytic herpes virus vectors |
| JP6092497B2 (ja) | 2006-03-30 | 2017-03-08 | ユニバーシティー オブ カリフォルニア | 抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物 |
| US8313896B2 (en) * | 2008-04-04 | 2012-11-20 | The General Hospital Corporation | Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer |
| WO2009148488A2 (en) | 2008-05-29 | 2009-12-10 | The General Hospital Corporation | Use of oncolytic herpes viruses for killing cancer stem cells |
| EP2356219A4 (en) | 2008-10-08 | 2017-07-05 | Intrexon Corporation | Engineered cells expressing multiple immunomodulators and uses thereof |
| US20100297072A1 (en) | 2009-05-19 | 2010-11-25 | Depinho Ronald A | Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy |
| WO2011063309A1 (en) | 2009-11-20 | 2011-05-26 | Infinity Pharmaceuticals, Inc. | Methods and compositions for treating hedgehog-associated cancers |
| WO2011119925A2 (en) * | 2010-03-25 | 2011-09-29 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthetic herpes simplex viruses for treatment of cancers |
| WO2011118866A1 (ko) | 2010-03-26 | 2011-09-29 | 연세대학교 산학협력단 | 네트워크를 통한 심사요청 방법 |
| KR20130108371A (ko) * | 2010-09-24 | 2013-10-02 | 온코스 테라퓨틱스 오와이 | 단클론 항―ｃｔｌａ－４ 항체를 암호화하는 종양분해 아데노바이러스 벡터 |
| ES2704632T3 (es) * | 2011-09-08 | 2019-03-19 | Univ New York | Virus de herpes simplex oncolítico y sus usos terapéuticos |
| FI20115914L (fi) | 2011-09-16 | 2013-03-17 | Oncos Therapeutics Ltd | Muunnettu onkolyyttinen virus |
| CN104427992B (zh) * | 2012-01-25 | 2017-12-19 | 德那翠丝有限公司 | 生物标志物及使用溶瘤病毒和免疫调节剂的组合疗法 |
| KR20170039774A (ko) | 2012-07-30 | 2017-04-11 | 알렉스 와 힌 영 | 종양 세포, 암세포파괴 바이러스 벡터 및 면역 체크포인트 조절인자를 갖는 암 백신 시스템 |
| AU2013308595C1 (en) | 2012-08-30 | 2019-01-17 | Amgen Inc. | A method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor |
| HK1213924A1 (zh) | 2012-10-23 | 2016-07-15 | Bristol-Myers Squibb Company | 用於治療癌症的抗kir和抗ctla-4抗體組合 |
| KR20150118159A (ko) | 2013-02-22 | 2015-10-21 | 에프. 호프만-라 로슈 아게 | 암의 치료 방법 및 약물 내성의 예방 방법 |
| US20160015760A1 (en) | 2013-03-14 | 2016-01-21 | Icahn School Of Medicine At Mount Sinai | Newcastle disease viruses and uses thereof |
| EA202191926A3 (ru) | 2013-09-03 | 2022-01-31 | Медиммун Лимитед | Композиции, содержащие аттенуированный вирус ньюкаслской болезни, и способы применения для лечения неоплазии |
| KR102272932B1 (ko) | 2013-10-25 | 2021-07-05 | 싸이오서스 테라퓨틱스 엘티디. | 이종 유전자로 무장된 종양살상 아데노바이러스 |
| EP3063279B1 (en) | 2013-10-28 | 2020-01-01 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Oncolytic hsv vector |
| AU2014352749A1 (en) | 2013-11-22 | 2016-06-09 | Dnatrix, Inc. | Adenovirus expressing immune cell stimulatory receptor agonist(s) |
| WO2015128313A1 (en) | 2014-02-25 | 2015-09-03 | Deutsches Krebsforschungszentrum | Rna viruses for immunovirotherapy |
| MA39818A (fr) * | 2014-03-30 | 2017-02-08 | Benevir Biopharm Inc | Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques |
| JP6895374B2 (ja) | 2014-07-16 | 2021-06-30 | トランジェーヌＴｒａｎｓｇｅｎｅ | 免疫チェックポイントモジュレーターの発現用腫瘍溶解性ウイルス |
| KR102504758B1 (ko) | 2014-07-16 | 2023-02-28 | 트랜스진 | 종양 세포 붕괴성 바이러스와 면역 체크포인트 조절제의 배합물 |
| US20160040186A1 (en) | 2014-08-07 | 2016-02-11 | Xiaoyun Liu | Dna construct and method for transgene expression |
| GB201419579D0 (en) | 2014-11-03 | 2014-12-17 | Iomet Pharma Ltd | Pharmaceutical compound |
| EP3247672B1 (en) | 2015-01-23 | 2018-11-28 | Dreamwell, Ltd. | Automated mattress manufacturing process and apparatus |
| MX2018008413A (es) * | 2016-01-08 | 2019-02-20 | Replimune Ltd | Virus oncolitico modificado. |
| KR102323872B1 (ko) | 2016-04-22 | 2021-11-08 | 임비라 컴퍼니 리미티드 | 암치료용 종양 용해성 단순 헤르페스 바이러스(oHSV) 절대 벡터 및 그 구조체의 구조 |
| GB201700350D0 (en) | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
| US12029647B2 (en) * | 2017-03-07 | 2024-07-09 | 4C Medical Technologies, Inc. | Systems, methods and devices for prosthetic heart valve with single valve leaflet |
| JP2021527694A (ja) | 2018-06-21 | 2021-10-14 | レプリミュン リミテッド | 腫瘍溶解性ウイルスを用いた処置 |
| WO2020124274A1 (en) | 2018-12-21 | 2020-06-25 | Ottawa Hospital Research Institute | Modified orthopoxvirus vectors |
-
2017
- 2017-01-09 MX MX2018008413A patent/MX2018008413A/es unknown
- 2017-01-09 JP JP2018555309A patent/JP6959258B2/ja active Active
- 2017-01-09 KR KR1020257002985A patent/KR20250026348A/ko active Pending
- 2017-01-09 ES ES17700385T patent/ES2841300T5/es active Active
- 2017-01-09 CA CA3011009A patent/CA3011009A1/en active Pending
- 2017-01-09 EP EP17700385.2A patent/EP3400291B2/en active Active
- 2017-01-09 US US16/068,823 patent/US10626377B2/en active Active
- 2017-01-09 DK DK20197725.3T patent/DK3805376T3/da active
- 2017-01-09 CA CA3010987A patent/CA3010987A1/en active Pending
- 2017-01-09 DK DK17701910.6T patent/DK3400293T4/da active
- 2017-01-09 ES ES17700384T patent/ES2943150T3/es active Active
- 2017-01-09 ES ES20197725T patent/ES3041885T3/es active Active
- 2017-01-09 ES ES17701910T patent/ES2831080T5/es active Active
- 2017-01-09 KR KR1020187022799A patent/KR102762431B1/ko active Active
- 2017-01-09 CA CA3011004A patent/CA3011004A1/en active Pending
- 2017-01-09 EP EP25185492.3A patent/EP4628577A2/en active Pending
- 2017-01-09 AU AU2017205216A patent/AU2017205216B2/en active Active
- 2017-01-09 EP EP17700386.0A patent/EP3400292B1/en active Active
- 2017-01-09 WO PCT/GB2017/050039 patent/WO2017118867A1/en not_active Ceased
- 2017-01-09 JP JP2018555310A patent/JP7038065B2/ja active Active
- 2017-01-09 EP EP20189881.4A patent/EP3778881A1/en active Pending
- 2017-01-09 WO PCT/GB2017/050036 patent/WO2017118864A1/en not_active Ceased
- 2017-01-09 DK DK17700384.5T patent/DK3400290T5/da active
- 2017-01-09 US US16/068,826 patent/US10570377B2/en active Active
- 2017-01-09 CN CN201780012527.8A patent/CN109415703B/zh active Active
- 2017-01-09 WO PCT/GB2017/050037 patent/WO2017118865A1/en not_active Ceased
- 2017-01-09 DK DK17700385.2T patent/DK3400291T4/da active
- 2017-01-09 SG SG11201805835WA patent/SG11201805835WA/en unknown
- 2017-01-09 US US16/068,816 patent/US10612005B2/en active Active
- 2017-01-09 SG SG10202108724YA patent/SG10202108724YA/en unknown
- 2017-01-09 US US16/068,830 patent/US10947513B2/en active Active
- 2017-01-09 EP EP23156055.8A patent/EP4219696A3/en active Pending
- 2017-01-09 EP EP17701910.6A patent/EP3400293B2/en active Active
- 2017-01-09 EP EP17700384.5A patent/EP3400290B1/en active Active
- 2017-01-09 CN CN201780012759.3A patent/CN109153977B/zh active Active
- 2017-01-09 JP JP2018555311A patent/JP7038664B2/ja active Active
- 2017-01-09 CN CN201780012579.5A patent/CN109312309B/zh active Active
- 2017-01-09 WO PCT/GB2017/050038 patent/WO2017118866A1/en not_active Ceased
- 2017-01-09 EP EP20197725.3A patent/EP3805376B1/en active Active
-
2018
- 2018-07-08 IL IL260480A patent/IL260480B/en active IP Right Grant
-
2020
- 2020-01-10 US US16/740,203 patent/US11473063B2/en active Active
- 2020-02-24 US US16/799,090 patent/US11427810B2/en active Active
-
2021
- 2021-02-01 US US17/164,635 patent/US12049647B2/en active Active
- 2021-05-06 IL IL282985A patent/IL282985B/en unknown
- 2021-10-05 JP JP2021163811A patent/JP7295192B2/ja active Active
-
2022
- 2022-03-07 JP JP2022034569A patent/JP2022078225A/ja active Pending
- 2022-08-03 US US17/817,245 patent/US12458696B2/en active Active
- 2022-08-04 US US17/817,618 patent/US12024724B2/en active Active
- 2022-12-01 AU AU2022279486A patent/AU2022279486B2/en active Active
-
2023
- 2023-02-02 US US18/163,837 patent/US12397053B2/en active Active
- 2023-06-08 JP JP2023094818A patent/JP2023113885A/ja active Pending
- 2023-09-06 US US18/462,133 patent/US12465639B2/en active Active
-
2024
- 2024-05-21 US US18/670,296 patent/US20240301365A1/en active Pending
- 2024-07-25 JP JP2024119344A patent/JP2024153748A/ja active Pending
-
2025
- 2025-07-23 US US19/277,600 patent/US20250352646A1/en active Pending
- 2025-07-31 JP JP2025128636A patent/JP2025163138A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019501671A5 (enExample) | ||
| JP2019501670A5 (enExample) | ||
| JP2019500909A5 (enExample) | ||
| JP2020503871A5 (enExample) | ||
| US20240358781A1 (en) | Altered virus | |
| JP7295192B2 (ja) | 改変された腫瘍溶解性ウイルス | |
| Guo et al. | Oncolytic immunotherapy: conceptual evolution, current strategies, and future perspectives | |
| Pol et al. | Trial Watch—Oncolytic viruses and cancer therapy | |
| US20210252135A1 (en) | Treatment using oncolytic virus | |
| CN112020510B (zh) | 包含用于治疗癌症的肿瘤抑制基因疗法和cd122/cd132激动剂的方法及组合物 | |
| US12331079B2 (en) | Oncolytic virus platform to treat cancers with myxoma virus | |
| CN107073099A (zh) | 用于治疗癌症的联合方法 | |
| TWI894135B (zh) | 編碼ccl21之重組棒狀病毒 | |
| JPWO2019243847A5 (enExample) | ||
| Zinovieva et al. | Oncolytic Vesicular Stomatitis Virus: Optimisation Strategies for Anti-Cancer Therapies | |
| US20230147975A1 (en) | Pharmaceutical formulation comprising a combination of recombinant newcastle disease viruses for the treatment of cancer | |
| Mani et al. | Study on Genetically Engineered Vesicular Stomatitis Virus for the Application of Treating Malignant Diseases using Gene Therapy | |
| WO2024120489A1 (en) | Use of dr-18 and oncolytic vaccinia virus in preparation of anti-tumor drug | |
| HK40045432A (en) | Modified oncolytic virus |